According to the Daily Telegraph, a new study has found that high levels of a protein called NAALADL2 were high in prostate cancer when compared with healthy tissue, and levels were higher in more aggressive and more extensive prostate tumours.
The level of the protein found in the tumours was also linked to whether men survived with or without recurrence of the cancer and overall survival after having radical prostatectomies, which is the surgery to remove cancer-ridden prostates.
However, it’s important to note that the research with the NAALADL2 protein is still at an early stage. So far, the work has been done only on tissue samples, not on blood. The diagnostic accuracy of a blood test (probably measuring levels of mRNA, the messenger used to make protein) needs to be investigated.
Hopefully, the researchers will be able to identify a test that could be performed on a patient to determine what type of cancer the person has. The researchers will use the blood samples for NAALADL2 to create a test that will identify those proteins and determine how risky the cancer is.
The most important aspect of this study is that, if a test were to be developed, it would need to be demonstrated through many controlled trials that is has the greatest benefit when compared with current diagnostic and staging methods, and ensure that it actually improved outcomes for men with prostate cancer.
About CenterForProstateCancer.org
The Center for Prostate Cancer (http://www.centerforprostatecancer.org) is dedicated to raising the awareness of prostate cancer and advanced robotic technologies for ways to detect, treat and destroy cancers of the prostate in men. If you are interested in learning more about advanced robotic technologies, visit the website today and see what options are available.
Distributed by Iterate LLC
Company Name:CenterForProstateCancer.org
Contact Person: Benjamin Wrights
Email:media@vytalnet.com
Phone: 4157669098
City: San Francisco
State: CA
Country: United States
Website: http://www.centerforprostatecancer.org
